Oral Recosulin set to revolutionize Diabetes market: Shreya

Mumbai, Nov 13 (UNI) The Oral Recosulin spray, developed by Canada-based Generex with Shreya Life Sciences, India, contributing the raw insulin crystals for the spray, is all set to revolutionize the Diabetes market in India, Shreya Domestic Business Director Ram Shelat said today.

Speaking on the occasion of launch the spray, Mr Shelat said, ''It's easy and safe to use with no side effects. The insulin spray goes directly to the patient's vascular system through the buccal mucosa (inner lining of cheeks) and the molecules are too large to be absorbed by the lungs. The fast reaction time of five-ten minutes will give patients flexibility in fixing their mealtimes post taking the insulin.'' The Oral Recosulin will come in a pack of one activator and two cannisters and is expected to retail for Rs 2,000 per pack following NPPA approval.

Generex executic advisor on Global Strategic Alliances William Abajain said that the company had spent over USD 200 million in research&development (R&D) in diabetic drugs including Oral Recusulin. ''This is a product that has eluded other big companies.

We are also waiting for clearances in 12 emerging markets in Asia, Latin America and the Middle East,'' Mr Abajain said.

UNI ZC SR SKB1738